ACA
PBYI icon

Acorn Capital Advisors’s Puma Biotechnology PBYI Stock Holding History

Acorn Capital Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.5M Hold
4,131,299
– – 9.14% 5
2026
Q1 		$26.4M Hold
4,131,299
– – 7.5% 4
2025
Q4 		$24.6M Hold
4,131,299
– – 8.33% 5
2025
Q3 		$21.9M Hold
4,131,299
– – 11.14% 3
2025
Q2 		$14.2M Buy
4,131,299
+191,247
+5% +$610K 9.27% 4
2025
Q1 		$11.7M Hold
3,940,052
– – 7.78% 6
2024
Q4 		$12M Buy
+3,940,052
New +$11.5M 6.47% 5

Other funds holding PBYI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return

Acorn Capital Advisors's PBYI Position: Q2 2026 in Review

Acorn Capital Advisors held its Puma Biotechnology (PBYI) position steady in Q2 2026 at 4,131,299 shares worth $33.5M. The position accounts for 9.14% of the portfolio, ranked #5.

Acorn Capital Advisors first reported a position in PBYI in Q4 2024 and has held it in 7 quarters since. 160 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Acorn Capital Advisors held 4,131,299 shares of Puma Biotechnology worth $33.5M as of Q2 2026.
  • Acorn Capital Advisors left its Puma Biotechnology share count unchanged in Q2 2026.
  • Puma Biotechnology made up 9.14% of Acorn Capital Advisors's portfolio in Q2 2026, its #5 holding.
  • Acorn Capital Advisors first reported a position in Puma Biotechnology in Q4 2024 and has held it in 7 quarters since.
  • 160 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Acorn Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.